Jérôme LeGoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jérôme LeGoff has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
François Simon
Virology, AP-HP, Hôpital Saint Louis, Paris, France
20 shared publicationsLinda Feghoul
Virology Department AP‐HP, Hôpital Saint Louis Paris France
16 shared publicationsSéverine Mercier-Delarue
16 shared publicationsLaurent Bélec
Laboratoire de Microbiologie, hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Sorbonne Paris Cité, Paris, France
15 shared publications- Maud Salmona
Hôpital Saint-Louis
15 shared publications Maud Salmona
Virology Department AP‐HP, Hôpital Saint Louis Paris France
13 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (7) , e71053
Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
Letermovir (LMV), a CMV‐specific terminase inhibitor, is recommended for cytomegalovirus (CMV) prophylaxis in CMV‐seropositive allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. The association between low‐level CMV DNAemia during prophylaxis and the emergence of mutations in CMV terminase complex genes remains unclear. We retrospectively analyzed 127 alloHSCT recipients at Saint‐Louis Hospital, Paris, receiving LMV prophylaxis (108 primary, 24 secondary, and 5 both). Weekly CMV DNAemia monitoring was performed, and samples with viral loads ≥ 3 log IU/mL underwent whole‐genome next‐generation sequencing to detect mutations in terminase complex genes. During LMV prophylaxis, CMV DNAemia was detected in 31.5% of primary and 62.5% of secondary prophylaxis patients; however, viral loads ≥ 3 log IU/mL remained low in both groups (8.3%). The frequency of polymorphisms in terminase complex genes increased 2.5‐fold during prophylaxis compared with pre‐prophylaxis, and then decreased 3.0‐fold after prophylaxis withdrawal. Confirmed LMV resistance was found in two patients, representing 1.6% of all patients and 18.2% of those with CMV DNAemia ≥ 3 log IU/mL. Two additional patients harbored mutations at resistance‐associated positions in UL56 and UL89, totaling 36% of patients with viral loads ≥ 3 log IU/mL displaying mutations at known resistance sites. Clinically significant CMV infections were successfully managed with preemptive therapies. This study confirms the efficacy of LMV prophylaxis and demonstrates that LMV exerts selective pressure on the terminase complex, increasing the risk of resistance when CMV DNA levels exceed 3 log IU/mL, underscoring the importance of timely consideration of alternative antiviral therapies when CMV replication persists.
- 10 July 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (7) , e71053
Open AccessSurveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
Letermovir (LMV), a CMV‐specific terminase inhibitor, is recommended for cytomegalovirus (CMV) prophylaxis in CMV‐seropositive allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. The association between low‐level CMV DNAemia during prophylaxis and the emergence of mutations in CMV terminase complex genes remains unclear. We retrospectively analyzed 127 alloHSCT recipients at Saint‐Louis Hospital, Paris, receiving LMV prophylaxis (108 primary, 24 secondary, and 5 both). Weekly CMV DNAemia monitoring was performed, and samples with viral loads ≥ 3 log IU/mL underwent whole‐genome next‐generation sequencing to detect mutations in terminase complex genes. During LMV prophylaxis, CMV DNAemia was detected in 31.5% of primary and 62.5% of secondary prophylaxis patients; however, viral loads ≥ 3 log IU/mL remained low in both groups (8.3%). The frequency of polymorphisms in terminase complex genes increased 2.5‐fold during prophylaxis compared with pre‐prophylaxis, and then decreased 3.0‐fold after prophylaxis withdrawal. Confirmed LMV resistance was found in two patients, representing 1.6% of all patients and 18.2% of those with CMV DNAemia ≥ 3 log IU/mL. Two additional patients harbored mutations at resistance‐associated positions in UL56 and UL89, totaling 36% of patients with viral loads ≥ 3 log IU/mL displaying mutations at known resistance sites. Clinically significant CMV infections were successfully managed with preemptive therapies. This study confirms the efficacy of LMV prophylaxis and demonstrates that LMV exerts selective pressure on the terminase complex, increasing the risk of resistance when CMV DNA levels exceed 3 log IU/mL, underscoring the importance of timely consideration of alternative antiviral therapies when CMV replication persists.
- Open Access
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
Metagenomic Analysis of Postmortem Cardiac Tissue for Diagnosing Fatal Viral Myocarditis: A Pilot Study
Background: Metagenomic next-generation sequencing may provide diagnostic information when conventional assays are inconclusive. Its role in myocarditis remains largely unexplored because cardiac samples are rarely available and viral burdens may be low.Objectives: To assess the diagnostic performance of metagenomic analysis in postmortem cardiac tissue from sudden cardiac death cases and compare it with viral RT-qPCR.Study design: Fresh frozen heart samples from 19 sudden cardiac death cases and 7 controls were analyzed. Cases included 14 patients without coronary artery disease and 5 with coronary artery disease. Controls were individuals who died from suicide or road traffic accidents and had no structural heart disease. Shotgun metagenomic sequencing and viral-enriched sequencing using the Illumina Virus Surveillance Panel were performed on cardiac nucleic acid extracts. Concordance with RT-qPCR was assessed using Cohen’s kappa coefficient.Results: Overall concordance between RT-qPCR and metagenomic approaches was poor. Neither method detected any viral target in patients with genetically confirmed or suspected channelopathies. In myocarditis cases, there was no agreement for enterovirus detection. For parvovirus B19, agreement was absent with shotgun metagenomics and slight with viral-enriched sequencing (kappa = 0.15). For HHV-6, agreement was slight with shotgun metagenomics (kappa = 0.25) and absent with viral-enriched sequencing. Additional viral sequences, including EBV and TTV, were detected by metagenomics, but their clinical significance remains uncertain.Conclusions: In this pilot study, metagenomic analysis of postmortem cardiac tissue showed limited added value and did not improve the etiologic diagnosis of presumed viral myocarditis.
- 9 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMetagenomic Analysis of Postmortem Cardiac Tissue for Diagnosing Fatal Viral Myocarditis: A Pilot Study
Background: Metagenomic next-generation sequencing may provide diagnostic information when conventional assays are inconclusive. Its role in myocarditis remains largely unexplored because cardiac samples are rarely available and viral burdens may be low.Objectives: To assess the diagnostic performance of metagenomic analysis in postmortem cardiac tissue from sudden cardiac death cases and compare it with viral RT-qPCR.Study design: Fresh frozen heart samples from 19 sudden cardiac death cases and 7 controls were analyzed. Cases included 14 patients without coronary artery disease and 5 with coronary artery disease. Controls were individuals who died from suicide or road traffic accidents and had no structural heart disease. Shotgun metagenomic sequencing and viral-enriched sequencing using the Illumina Virus Surveillance Panel were performed on cardiac nucleic acid extracts. Concordance with RT-qPCR was assessed using Cohen’s kappa coefficient.Results: Overall concordance between RT-qPCR and metagenomic approaches was poor. Neither method detected any viral target in patients with genetically confirmed or suspected channelopathies. In myocarditis cases, there was no agreement for enterovirus detection. For parvovirus B19, agreement was absent with shotgun metagenomics and slight with viral-enriched sequencing (kappa = 0.15). For HHV-6, agreement was slight with shotgun metagenomics (kappa = 0.25) and absent with viral-enriched sequencing. Additional viral sequences, including EBV and TTV, were detected by metagenomics, but their clinical significance remains uncertain.Conclusions: In this pilot study, metagenomic analysis of postmortem cardiac tissue showed limited added value and did not improve the etiologic diagnosis of presumed viral myocarditis.
- 11 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Shotgun metagenomic sequencing improves cross‐kingdom diagnosis of mycetoma
- 11 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Shotgun metagenomic sequencing improves cross‐kingdom diagnosis of mycetoma
- Open Access
- 9 October 2025
- Published by Wiley
Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
Background : Letermovir (LMV), a CMV-specific terminase inhibitor, is recommended for cytomegalovirus (CMV) prophylaxis in CMV-seropositive allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. The association between low-level CMV DNAemia during prophylaxis and the emergence of mutations in CMV terminase complex genes remains unclear. Methods : We retrospectively analyzed 127 alloHSCT recipients at Saint-Louis Hospital, Paris, receiving LMV prophylaxis (108 primary, 24 secondary, 5 both). Weekly CMV DNAemia monitoring was performed, and samples with viral loads ≥3 log IU/mL underwent whole-genome next-generation sequencing to detect mutations in terminase complex genes. Results : During LMV prophylaxis, CMV DNAemia was detected in 31.5% of primary and 62.5% of secondary prophylaxis patients; however, viral loads ≥3 log IU/mL remained low in both groups (8.3%). The frequency of polymorphisms in terminase complex genes increased 2.5-fold during prophylaxis compared with pre-prophylaxis, and then decreased 3.0-fold after prophylaxis withdrawal. Confirmed LMV resistance was found in two patients, representing 1.6% of all patients and 18.2% of those with CMV DNAemia ≥ 3 log IU/mL. Two additional patients harbored mutations at resistance-associated positions in UL56 and UL89, totaling 36% of patients with viral loads ≥3 log IU/mL displaying mutations at known resistance sites. Clinically significant CMV infections were successfully managed with preemptive therapies. Conclusions : This study confirms the efficacy of LMV prophylaxis and demonstrates that LMV exerts selective pressure on the terminase complex, increasing the risk of resistance when CMV DNA levels exceed 3 log IU/mL, underscoring the importance of timely consideration of alternative antiviral therapies when CMV replication persists.
- 9 October 2025
- Published by Wiley
Open AccessSurveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
Background : Letermovir (LMV), a CMV-specific terminase inhibitor, is recommended for cytomegalovirus (CMV) prophylaxis in CMV-seropositive allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. The association between low-level CMV DNAemia during prophylaxis and the emergence of mutations in CMV terminase complex genes remains unclear. Methods : We retrospectively analyzed 127 alloHSCT recipients at Saint-Louis Hospital, Paris, receiving LMV prophylaxis (108 primary, 24 secondary, 5 both). Weekly CMV DNAemia monitoring was performed, and samples with viral loads ≥3 log IU/mL underwent whole-genome next-generation sequencing to detect mutations in terminase complex genes. Results : During LMV prophylaxis, CMV DNAemia was detected in 31.5% of primary and 62.5% of secondary prophylaxis patients; however, viral loads ≥3 log IU/mL remained low in both groups (8.3%). The frequency of polymorphisms in terminase complex genes increased 2.5-fold during prophylaxis compared with pre-prophylaxis, and then decreased 3.0-fold after prophylaxis withdrawal. Confirmed LMV resistance was found in two patients, representing 1.6% of all patients and 18.2% of those with CMV DNAemia ≥ 3 log IU/mL. Two additional patients harbored mutations at resistance-associated positions in UL56 and UL89, totaling 36% of patients with viral loads ≥3 log IU/mL displaying mutations at known resistance sites. Clinically significant CMV infections were successfully managed with preemptive therapies. Conclusions : This study confirms the efficacy of LMV prophylaxis and demonstrates that LMV exerts selective pressure on the terminase complex, increasing the risk of resistance when CMV DNA levels exceed 3 log IU/mL, underscoring the importance of timely consideration of alternative antiviral therapies when CMV replication persists.
- 23 August 2025
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (12) , 2073-2081
Clinical significance of respiratory torque teno virus in immunocompromised patients with acute respiratory failure
- 23 August 2025
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (12) , 2073-2081
Clinical significance of respiratory torque teno virus in immunocompromised patients with acute respiratory failure
- Open Access
- 22 May 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (5) , e70411
Clinical and Epidemiological Insights into a Parainfluenza Virus Type 3 Outbreak in Multiple Myeloma Patients
Human parainfluenza virus type 3 (HPIV‐3) can be responsible for mild to severe respiratory infections and hospital epidemics. We investigated an outbreak in a hematology unit. Respiratory viruses were screened using multiplex PCR. HPIV‐3 quantification and whole‐genome sequencing were performed on HPIV‐3 positive respiratory samples. Clinical characteristics, infection progression, incidence rates of respiratory viruses within the hospital and detection of respiratory viruses were documented, along with the reinforcement of infection prevention and control (IPC) measures implemented. Between November 2022, and January 2023, HPIV‐3 was identified in 20 of 113 hematology patients (17.7%), of whom 80% had multiple myeloma. A majority of HPIV‐3‐positive patients developed pneumonia (60%), and mortality was notably higher (35%) compared to patients who were negative (3%, p < 0.0001). Respiratory HPIV‐3 viral loads were similar between patients with and without pneumonia. In parallel, HPIV‐3 incidence in the hospital overall was lower than in the hematology unit (p < 0.0001). Air virus screening showed the detection of HPIV‐3 in the air in different areas, and whole‐genome sequencing confirmed the circulation of a single HPIV‐3 strain. Strengthened IPC measures were associated with the containment of the outbreak. HPIV‐3 has high epidemic potential in patients with multiple myeloma and causes severe infections. Our findings highlight the need for routine HPIV‐3 testing in hematology units.
- 22 May 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (5) , e70411
Open AccessClinical and Epidemiological Insights into a Parainfluenza Virus Type 3 Outbreak in Multiple Myeloma Patients
Human parainfluenza virus type 3 (HPIV‐3) can be responsible for mild to severe respiratory infections and hospital epidemics. We investigated an outbreak in a hematology unit. Respiratory viruses were screened using multiplex PCR. HPIV‐3 quantification and whole‐genome sequencing were performed on HPIV‐3 positive respiratory samples. Clinical characteristics, infection progression, incidence rates of respiratory viruses within the hospital and detection of respiratory viruses were documented, along with the reinforcement of infection prevention and control (IPC) measures implemented. Between November 2022, and January 2023, HPIV‐3 was identified in 20 of 113 hematology patients (17.7%), of whom 80% had multiple myeloma. A majority of HPIV‐3‐positive patients developed pneumonia (60%), and mortality was notably higher (35%) compared to patients who were negative (3%, p < 0.0001). Respiratory HPIV‐3 viral loads were similar between patients with and without pneumonia. In parallel, HPIV‐3 incidence in the hospital overall was lower than in the hematology unit (p < 0.0001). Air virus screening showed the detection of HPIV‐3 in the air in different areas, and whole‐genome sequencing confirmed the circulation of a single HPIV‐3 strain. Strengthened IPC measures were associated with the containment of the outbreak. HPIV‐3 has high epidemic potential in patients with multiple myeloma and causes severe infections. Our findings highlight the need for routine HPIV‐3 testing in hematology units.
- 25 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Investigating Nosocomial BK Polyomavirus Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Challenges and Prospects
Background: The modes of transmission of BK polyomavirus (BKPyV) remain incompletely understood. BKPyV infections can lead to hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT). Hospitalization in a pediatric hematology unit may represent initial exposure to BKPyV due to the high rate of viral shedding among hematology patients. This study explores the potential for nosocomial transmission of BKPyV within a hematology department. Methods: Epidemiologic investigation and BKPyV genome phylogenetic analyses were conducted among individuals with BKPyV DNAuria and/or DNAemia over a 3-year period in a pediatric hematology unit. Results: From November 2019 to December 2022, BKPyV DNA was detected in the urine or plasma of 34 of 173 children following HSCT. An unusually high prevalence of genotype Ia BKPyV was observed in 2021, suggesting possible patient-to-patient transmission. However, despite closely related sequences, they clustered with several GenBank entries, complicating phylogenetic linkage determination. Genetic signature analysis also did not link these sequences to specific patient clinical profiles. Discussion: This study highlights the complexity of establishing nosocomial transmission of BKPyV, even with viral sequence analyses. Future prospective studies should include noncoding control region analysis, serological data, and environmental factors to enhance understanding of BKPyV transmission routes.
- 25 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Investigating Nosocomial BK Polyomavirus Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Challenges and Prospects
Background: The modes of transmission of BK polyomavirus (BKPyV) remain incompletely understood. BKPyV infections can lead to hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT). Hospitalization in a pediatric hematology unit may represent initial exposure to BKPyV due to the high rate of viral shedding among hematology patients. This study explores the potential for nosocomial transmission of BKPyV within a hematology department. Methods: Epidemiologic investigation and BKPyV genome phylogenetic analyses were conducted among individuals with BKPyV DNAuria and/or DNAemia over a 3-year period in a pediatric hematology unit. Results: From November 2019 to December 2022, BKPyV DNA was detected in the urine or plasma of 34 of 173 children following HSCT. An unusually high prevalence of genotype Ia BKPyV was observed in 2021, suggesting possible patient-to-patient transmission. However, despite closely related sequences, they clustered with several GenBank entries, complicating phylogenetic linkage determination. Genetic signature analysis also did not link these sequences to specific patient clinical profiles. Discussion: This study highlights the complexity of establishing nosocomial transmission of BKPyV, even with viral sequence analyses. Future prospective studies should include noncoding control region analysis, serological data, and environmental factors to enhance understanding of BKPyV transmission routes.
- Open Access
- 30 July 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (8) , e29836
Combined Flow‐Fluorescence in situ hybridization to HHV‐8 and EBV reveals the viral heterogeneity of primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare B‐cell non‐Hodgkin lymphoma associated with Kaposi Sarcoma‐associated herpesvirus (KSHV/HHV8) infection. Lymphoma cells are coinfected with Epstein‐Barr virus (EBV) in 60−80% of cases. Tools allowing a reliable PEL diagnosis are lacking. This study reports PEL diagnosis in 4 patients using a Flow‐Fluorescence in situ hybridization (FlowFISH) technique that allowed detection of differentially expressed EBV and HHV8 transcripts within the same sample, revealing viral heterogeneity of the disease. Moreover, infected cells exhibited variable expressions of CD19, CD38, CD40, and CD138. Therefore, FlowFISH is a promising tool to diagnose and characterize complex viral lymphoproliferations.
- 30 July 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (8) , e29836
Open AccessCombined Flow‐Fluorescence in situ hybridization to HHV‐8 and EBV reveals the viral heterogeneity of primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare B‐cell non‐Hodgkin lymphoma associated with Kaposi Sarcoma‐associated herpesvirus (KSHV/HHV8) infection. Lymphoma cells are coinfected with Epstein‐Barr virus (EBV) in 60−80% of cases. Tools allowing a reliable PEL diagnosis are lacking. This study reports PEL diagnosis in 4 patients using a Flow‐Fluorescence in situ hybridization (FlowFISH) technique that allowed detection of differentially expressed EBV and HHV8 transcripts within the same sample, revealing viral heterogeneity of the disease. Moreover, infected cells exhibited variable expressions of CD19, CD38, CD40, and CD138. Therefore, FlowFISH is a promising tool to diagnose and characterize complex viral lymphoproliferations.
- Open Access
- 22 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107281
Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant
- 22 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107281
Open AccessZanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant